Dr. Mohammed S. Bukari, MD
Hematology & Oncology (Hematology & Oncology Physician)
785 Medical Center Drive West, 203
Clovis, CA 93611
Who else practices at this address →
Fresno County includes primary care (14% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 589
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A150043 (first issued 2017; current) -
Hospitalist Physician
CA license A150043 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Community Regional Medical Center Fresno, CA
- Clovis Community Medical Center Clovis, CA
Medical groups
- Community Health PArtners (504 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 589
- Services billed
- 1,830
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 625 | 231 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 109 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 83 | 76 |
| New patient office or other outpatient visit, 45-59 minutes | 64 | 64 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 57 | 32 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 49 | 48 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 42 | 26 |
| Injection of drug or substance under skin or into muscle | 42 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Clovis, CA | 249 |
| Acyclovir Other prescribers in Clovis, CA | 203 |
| Allopurinol Other prescribers in Clovis, CA | 174 |
| Gabapentin Other prescribers in Clovis, CA | 116 |
| Pantoprazole Sodium Other prescribers in Clovis, CA | 113 |
| Potassium Chloride Other prescribers in Clovis, CA | 105 |
| Hydroxyurea Other prescribers in Clovis, CA | 99 |
| Lenalidomide | 94 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Clovis, CA | 69 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Clovis, CA | 60 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 89 payments worth $10,510 in total to this clinician.
| Agios Pharmaceuticals, Inc. | $6,519 |
|---|---|
| Stemline Therapeutics Inc. | $2,191 |
| Astellas Pharma US Inc | $217 |
| Daiichi Sankyo Inc. | $177 |
| Janssen Scientific Affairs, LLC | $150 |
| GlaxoSmithKline, LLC. | $140 |
| E.r. Squibb & Sons, L.l.c. | $118 |
| Sobi, Inc | $99.00 |
| Consulting Fee | $7,870 |
|---|---|
| Food and Beverage | $1,710 |
| Travel and Lodging | $644 |
| Education | $287 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. Jun 18, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $5,550 |
| Stemline Therapeutics Inc. May 2, 2025 | Consulting Fee ELZONRIS · Oncology | $2,170 |
| Agios Pharmaceuticals, Inc. May 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Los Angeles, CA | $365 |
| Agios Pharmaceuticals, Inc. May 17, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Los Angeles, CA | $227 |
| Janssen Scientific Affairs, LLC Aug 15, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| Sobi, Inc Jan 17, 2025 | Education in-kind | $99.00 |
| Astellas Pharma US Inc Jan 8, 2025 | Education in-kind | $99.00 |
| Seagen Inc. Apr 28, 2025 | Education in-kind | $89.00 |
| Agios Pharmaceuticals, Inc. Jun 18, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Los Angeles, CA | $52.06 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $102,010 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie Inc. · Recruiting · NCT06428019 - A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First …
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.